MORIGI, ALICE
 Distribuzione geografica
Continente #
NA - Nord America 508
EU - Europa 406
AS - Asia 275
AF - Africa 36
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 1227
Nazione #
US - Stati Uniti d'America 504
VN - Vietnam 184
SE - Svezia 145
GB - Regno Unito 96
IT - Italia 60
CN - Cina 55
DE - Germania 43
IN - India 30
TG - Togo 28
FR - Francia 24
RU - Federazione Russa 17
ZA - Sudafrica 8
EE - Estonia 6
UA - Ucraina 5
CA - Canada 4
ES - Italia 2
HK - Hong Kong 2
IR - Iran 2
RO - Romania 2
BE - Belgio 1
CL - Cile 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
EU - Europa 1
FI - Finlandia 1
LB - Libano 1
NO - Norvegia 1
OM - Oman 1
PL - Polonia 1
Totale 1227
Città #
Fairfield 95
Dong Ket 93
Southend 87
Princeton 44
Ashburn 41
Chandler 41
Houston 41
Seattle 30
Lomé 28
Wilmington 27
Woodbridge 26
Berlin 25
Cambridge 23
Ann Arbor 22
Bologna 16
Redmond 13
Westminster 10
Nanjing 9
Beijing 8
Des Moines 7
Jinan 7
San Diego 7
Shenyang 7
Jiaxing 5
Redwood City 5
Saint Petersburg 5
Rome 4
Guangzhou 3
Hangzhou 3
Padova 3
Toronto 3
Falls Church 2
Medford 2
Norwalk 2
Santa Marinella 2
Tianjin 2
Zhengzhou 2
Andover 1
Arzano 1
Barrie 1
Bonn 1
Brussels 1
Canino 1
Changsha 1
Dearborn 1
Desio 1
Eden Prairie 1
Frankfurt Am Main 1
Fremont 1
Fuzhou 1
Gallo 1
Haikou 1
Hebei 1
Helsinki 1
Kuban 1
Las Vegas 1
London 1
Lviv 1
Madrid 1
Marino 1
Milan 1
Monmouth Junction 1
Nanchang 1
Novokuznetsk 1
Phoenix 1
Pitesti 1
Plauen 1
Porto Garibaldi 1
Provo 1
Ravenna 1
San Francisco 1
Stazzano 1
Taizhou 1
Torino 1
Wuhan 1
Zanjan 1
Totale 789
Nome #
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years 137
The Berlin-Frankfurt-Münster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience 117
Long-term responders after Brentuximab vedotin: Single-center experience on relapsed and refractory hodgkin lymphoma and anaplastic large cell lymphoma patients 104
BRAF V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia 92
The treatment of primary mediastinal large B-cell lymphoma: A two decades monocentric experience with 98 patients 89
PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series 86
(90) Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study 85
Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma 81
Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients 81
A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies 72
Granulomatous tattoo reaction in a nivolumab-treated patient 62
Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma 45
Successful stem cell harvest and autologous transplantation in a patient with cold agglutinin syndrome and aggressive lymphoma 40
Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients 39
Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience 36
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience 30
Spontaneous remission of follicular lymphoma 26
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 23
Long-term efficacy and safety of ibrutinib in the treatment of CLL patients: A real life experience 20
Intravascular Large B-cell Lymphoma Successfully Treated with Autologous Transplantation 16
Prolonged responses to brentuximab vedotin as last therapy in Hodgkin lymphoma failing autologous transplantation: A case series 14
The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience 11
Totale 1306
Categoria #
all - tutte 1902
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1902


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/20189 0000 10 00 0080
2018/201935 0300 23 44 0784
2019/2020262 33617 3721 2639 33281516
2020/2021313 3491211 76 515 40916149
2021/2022480 81111643 3018 336 135710666
2022/2023198 46100493 00 00 0000
Totale 1306